Literature DB >> 1642654

Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis.

P Miossec1, J Briolay, J Dechanet, J Wijdenes, H Martinez-Valdez, J Banchereau.   

Abstract

OBJECTIVE: To assess the spontaneous production of proinflammatory cytokines and immunoglobulins in rheumatoid arthritis (RA) synovitis and modulation by interleukin-4 (IL-4).
METHODS: We developed an ex vivo model of RA synovitis using pieces of RA synovium, and have studied the regulation of the production of IL-1 beta, IL-6, tumor necrosis factor alpha (TNF alpha), IgM, and IgG.
RESULTS: Spontaneous production of proinflammatory cytokines in vitro was active, with prolonged cytokine gene transcription and translation. IL-6 was produced at higher levels than either IL-1 beta or TNF alpha, and explants produced more IgG than IgM. In contrast, IL-4 and interferon-gamma were undetectable. When pieces of synovium were incubated in the presence of IL-4, reduction of spontaneous proinflammatory cytokine and Ig production was observed.
CONCLUSION: These results extend the observations of the antiinflammatory properties of IL-4 to an ex vivo situation, and provide the rationale for the clinical use of IL-4 in RA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642654     DOI: 10.1002/art.1780350805

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  37 in total

1.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

Authors:  A C Bendixen; N K Shevde; K M Dienger; T M Willson; C D Funk; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

Review 2.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

3.  Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.

Authors:  Y Morita; J Yang; R Gupta; K Shimizu; E A Shelden; J Endres; J J Mulé; K T McDonagh; D A Fox
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

4.  The influence of interleukin-4 on ligament healing.

Authors:  Connie S Chamberlain; Ellen M Leiferman; Kayt E Frisch; Sijian Wang; Xipei Yang; Stacey L Brickson; Ray Vanderby
Journal:  Wound Repair Regen       Date:  2011-04-21       Impact factor: 3.617

Review 5.  Angiogenesis as a target in rheumatoid arthritis.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

6.  Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclo-oxygenase I.

Authors:  E Sugiyama; H Taki; A Kuroda; T Mino; N Yamashita; M Kobayashi
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

7.  The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium.

Authors:  J Dechanet; P Merville; I Durand; J Banchereau; P Miossec
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

8.  The Th1-Th2 model--what relevance to inflammatory arthritis?

Authors:  P D Kiely
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

9.  Local effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine calvarium.

Authors:  Allison J Rao; Christophe Nich; Lakshmi S Dhulipala; Emmanuel Gibon; Roberto Valladares; Stefan Zwingenberger; R Lane Smith; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2012-12-05       Impact factor: 4.396

10.  In vitro differentiation of peripheral blood T cells towards a type 2 phenotype is impaired in rheumatoid arthritis (RA).

Authors:  S Asselin; H Conjeaud; D Fradelizi; M Breban
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.